ITM Isotope Technologies Munich SE Received a Complete Response Letter (CRL) From the US Food and Drug Administration on August 7, 2026 for 177Lu-Edotreotide (ITM-11), a Somatostatin Analog Radioligand Peptide Therapeutic Under Investigation for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs); The CRL Cited Chemistry, Manufacturing, and Controls (CMC) and Third-Party Commercial Manufacturing Facility Items to Address Before Resubmission, but the FDA Did Not Identify Any Concerns Regarding the Clinical Data Package, Nonclinical Data, or Safety Profile of ITM-11; The Company Intends to Resubmit to Complete the NDA Review and Continues to Pursue Approval Following the COMPETE Trial (NCT03049189) Phase 3 Comparison of 177Lu-Edotreotide Versus Everolimus in Inoperable Progressive Grade 1 or Grade 2 GEP-NETs
ITM Isotope Technologies Munich SE received a Complete Response Letter (CRL) from the US FDA on August 7, 2026, disclosed August 10-11, for 177Lu-edotreotide (ITM-11), a somatostatin analog radioligand peptide therapeutic under investigation for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The CRL cited chemistry, manufacturing, and controls (CMC) and third-party commercial manufacturing facility items that must be addressed before the application can be approved. Notably, the FDA did not identify any concerns regarding the clinical data package, nonclinical data, or safety profile of ITM-11. The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide compared to everolimus (an oral mTOR inhibitor targeted molecular therapy) in patients with inoperable, progressive Grade 1 or Grade 2 GEP-NETs. ITM-11 is a peptide radioligand therapy: a somatostatin receptor 2 (SSTR2)-targeting peptide chelated to the beta-emitting radionuclide lutetium-177 to deliver targeted radiation to SSTR2-expressing neuroendocrine tumor cells. The category is anchored commercially by Novartis's Lutathera (177Lu-dotatate) and Pluvicto (177Lu-vipivotide tetraxetan, PSMA-targeting for prostate cancer). ITM intends to resubmit and complete the NDA review process. The manufacturing-focused CRL is a substantially better outcome than a clinical-data CRL: resolution timelines for CMC-only CRLs typically run 4-8 months versus 12+ months for data-driven CRLs, and the fundamental commercial thesis remains intact.